Owner of DOGE Meme Shiba Inu Clarifies: CATE Token Unrelated, Only Endorses DOG and COCORO Projects
On July 28, Atsuko Sato, owner of the Doge meme Shiba Inu Kabosu, issued a statement clarifying that a series of CATE tokens circulating in the market recently have no connection to her. She stated that she had only posted a story on Instagram, but the content was subsequently used without authorization by others to issue fake tokens, creating a false impression of association. She expressed regret over this and pointed out that among the accounts spreading related information were even some users with significant influence on the X platform. She emphasized that the only project officially authorized to manage her intellectual property is Own The Doge. She explained that Own The Doge acquired the Doge NFT in 2021 and launched the DOG token, while also organizing Doge Day events, supporting charitable causes, and managing her intellectual property. In 2025, the two parties collaborated to launch the COCORO token on the Base network. She stated that the proceeds from these projects will be used to care for her pet family members and support the animal protection charity activities carried out by withkabosu. She called on the public to rely on official information and to be vigilant against any unauthorized projects or tokens issued under her name, avoiding mistakenly trusting crypto asset projects unrelated to her.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Analyst Gu Jingci: Follow the trend and adapt flexibly
XRP Ledger adds account control feature, enabling enterprises to manage assets offline.
BUZZ - Goldman Sachs says the price cap on cancer drugs has limited impact on Indian hospitals
October 9 – Goldman Sachs pointed out that India's implementation of a 30% profit margin cap on non-scheduled anticancer drugs (link) will have limited impact on hospitals. The report states that, based on preliminary discussions with hospital chain groups, such drugs account for less than 5% of hospital revenue and 2% to 2.5% of operating profit. The report adds that hospitals can offset the losses by slightly adjusting service charges, such as administration fees. According to a government notice, an expert committee will finalize the list of drugs to be brought under regulation. Driven by the anticipated price cap, the share prices of Max Healthcare MAXE.NS, Apollo Hospitals APLH.NS, and Fortis Healthcare FOHE.NS rose by 1.6% to 2.5%. Previously, since September 30, these stocks had collectively declined by 11% to 11.5%. Year-to-date, FOHE and MAXE are down 11.7% and 14.8%, respectively, while APLH has risen by 11%. (To assist non-English speakers, Reuters provides automated translations of its reports into several other languages. Due to potential errors or missing context in automated translations, Reuters does not guarantee the accuracy of automatic translation texts and offers them solely for readers’ convenience. Reuters accepts no responsibility for any damage or loss caused by using these automated translation features.)
Adding insult to injury! Japanese electronics giant Nidec downgraded by UBS, stock price plunges over 9% and approaches an 11-month low
UBS has downgraded Nidec's rating from "Buy" to "Neutral" and lowered its target price from 2,800 yen to 2,400 yen, citing a more challenging market environment.
Crypto prices
More
